Effects of a single dose of terlipressin on transcutaneous oxygen pressures

Aleksander Krag, Søren Møller, Jens H Henriksen, Flemming Bendtsen

Research output: Contribution to journalJournal articleResearchpeer-review

7 Citations (Scopus)

Abstract

Abstract Objective. Terlipressin (TP) is a potent vasoconstrictor, which is widely used in the treatment of bleeding esophageal varices and the hepatorenal syndrome. Side effects to TP are often related to skin hypoxaemia. The aim of the study was to investigate the transcutaneous oxygen pressures (TcPO(2) mmHg) after administration of 2 mg of TP. Patients and methods. Nineteen patients with cirrhosis and ascites were included. TcPO(2) mmHg were measured continuously measured at the chest, abdominal wall and at the lower extremity at baseline and after 2 mg TP in 15 patients and placebo in 4 patients. Results. The mean whole body TcPO(2) decreased after TP by 34% (p < 0.005). The decrease was even more pronounced in the lower extremity: above knee -33% (50 vs. 33 mmHg, p = 0.01) and below knee -52% (52 vs. 26 mmHg, p = 0.001). Levels below 30 mmHg, were found in 60% of the patients after TP compared to 0% in the placebo group, p = 0.005. There were no significant changes in TcPO(2) after placebo. The baseline leg TcPO(2) correlated inversely with the MELD score (r = -0.64 and p < 0.003) and the increase in MAP after TP correlated inversely with TcPO(2) at the thorax (r = -0.60, p = 0.009). Conclusions. Sixty percent of patients with decompensated cirrhosis develop hypoxaemia in the lower limb after one dose of TP.
Original languageEnglish
JournalScandinavian Journal of Gastroenterology
Volume45
Issue number7-8
Pages (from-to)953-958
Number of pages6
ISSN0036-5521
DOIs
Publication statusPublished - 2010

Keywords

  • Adult
  • Anoxia
  • Blood Gas Monitoring, Transcutaneous
  • Female
  • Humans
  • Lypressin
  • Male
  • Middle Aged
  • Vasoconstrictor Agents

Cite this